FMOD was suggested to be a tumor-associated antigen in chronic lymphocytic leukemia (CLL) (Mayr et al., 2005); in clinical samples obtained from prostate cancer patients, significant variations of FMOD expression were observed between benign and malignant tissues (Reyes et al., 2016); and a recent study implicated FMOD in glioma cell migration (Mondal et al., 2017). The gene discussed is FMOD; the disease is prostate carcinoma.